Introduction: Uterine leiomyomas, or fibroids, are prevalent benign tumors affecting up to 70% of reproductive-age women in the United States, significantly impacting productivity and quality of life. Despite their commonality, the epidemiology and clinical patterns of leiomyomas in Puerto Rico remain inadequately researched. Methods: This study conducted a secondary data analysis using clinical, menstrual cycle characteristics, and demographic data from self-administered questionnaires of women undergoing diagnostic laparoscopy for endometriosis in Puerto Rico. Chi-square tests and t-tests analyzed categorical and continuous variables, respectively (p < 0.05, R 4.1.0 software). Results: Among 1,610 endometriosis cases, 312 included uterine fibroids. Prevalence estimates were 10.3% (<30 years), 36.9% (30 - 40 years), and 52.6% (>40 years). Primiparous women averaged 22.14 years, with 40.71% having 2 - 3 pregnancies and 26.28% experiencing miscarriages. Symptoms included infertility (29.5%), dyspareunia (40.7%), severe pain (50%), and dysmenorrhea (75.6%). Comorbidities included ovarian cysts (52.2%) and abnormal uterine bleeding (37.8%). Conclusions: Advanced age, parity, and comorbidities like diabetes and hypertension were prevalent in our cohort. Understanding the epidemiological profile of women living in Puerto Rico with uterine fibroids is crucial for improving diagnostic awareness and enhancing patient care.
References
[1]
Baranov, V.S., Osinovskaya, N.S. and Yarmolinskaya, M.I. (2019) Pathogenomics of Uterine Fibroids Development. International Journal of Molecular Sciences, 20, Article No. 6151. https://doi.org/10.3390/ijms20246151
[2]
Giuliani, E., As-Sanie, S. and Marsh, E.E. (2020) Epidemiology and Management of Uterine Fibroids. International Journal of Gynecology & Obstetrics, 149, 3-9. https://doi.org/10.1002/ijgo.13102
[3]
Huang, D., et al. (2022) Fibroid Prevalence and Burden by Race in an Asymptomatic, Diverse Cohort of Reproductive-Age Women. Fertility and Sterility, 118, e37-e38.
[4]
Li, B., Wang, F., Chen, L. and Tong, H. (2023) Global Epidemiological Characteristics of Uterine Fibroids. Archives of Medical Science, 19, 1802-1810. https://doi.org/10.5114/aoms/171786
[5]
Cardozo, E.R., Clark, A.D., Banks, N.K., Henne, M.B., Stegmann, B.J. and Segars, J.H. (2012) The Estimated Annual Cost of Uterine Leiomyomata in the United States. American Journal of Obstetrics and Gynecology, 206, 211.e1-211.e9. https://doi.org/10.1016/j.ajog.2011.12.002
[6]
Whiteman, M.K., Kuklina, E., Jamieson, D.J., Hillis, S.D. and Marchbanks, P.A. (2010) Inpatient Hospitalization for Gynecologic Disorders in the United States. American Journal of Obstetrics and Gynecology, 202, 541.e1-541.e6. https://doi.org/10.1016/j.ajog.2009.12.013
[7]
Stewart, E.A., Laughlin-Tommaso, S.K., Catherino, W.H., Lalitkumar, S., Gupta, D. and Vollenhoven, B. (2016) Uterine fibroids. Nature Reviews Disease Primers, 2, Article No. 16043. https://doi.org/10.1038/nrdp.2016.43
[8]
Flores, I., Abreu, S., Abac, S., Fourquet, J., Laboy, J. and Ríos-Bedoya, C. (2007) Self-Reported Prevalence of Endometriosis and Its Symptoms among Puerto Rican Women. International Journal of Gynecology & Obstetrics, 100, 257-261. https://doi.org/10.1016/j.ijgo.2007.08.010
[9]
Bartels, C.B., Cayton, K.C., Chuong, F.S., Holthouser, K., Mehr, S.A., Abraham, T., et al. (2016) An Evidence-Based Approach to the Medical Management of Fibroids. Clinical Obstetrics & Gynecology, 59, 30-52. https://doi.org/10.1097/grf.0000000000000171
[10]
Khan, A., Shehmar, M. and Gupta, J. (2014) Uterine Fibroids: Current Perspectives. International Journal of Women’s Health, 6, 95-114. https://doi.org/10.2147/ijwh.s51083
[11]
Marsh, E.E., Al-Hendy, A., Kappus, D., Galitsky, A., Stewart, E.A. and Kerolous, M. (2018) Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. Journal of Women’s Health, 27, 1359-1367. https://doi.org/10.1089/jwh.2018.7076
[12]
Flake, G.P., Andersen, J. and Dixon, D. (2003) Etiology and Pathogenesis of Uterine Leiomyomas: A Review. Environmental Health Perspectives, 111, 1037-1054. https://doi.org/10.1289/ehp.5787
[13]
Yang, Q., Ciebiera, M., Bariani, M.V., Ali, M., Elkafas, H., Boyer, T.G., et al. (2021) Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocrine Reviews, 43, 678-719. https://doi.org/10.1210/endrev/bnab039
[14]
Eltoukhi, H.M., Modi, M.N., Weston, M., Armstrong, A.Y. and Stewart, E.A. (2014) The Health Disparities of Uterine Fibroid Tumors for African American Women: A Public Health Issue. American Journal of Obstetrics and Gynecology, 210, 194-199. https://doi.org/10.1016/j.ajog.2013.08.008
[15]
Downes, E., Sikirica, V., Gilabert-Estelles, J., Bolge, S.C., Dodd, S.L., Maroulis, C., et al. (2010) The Burden of Uterine Fibroids in Five European Countries. European Journal of Obstetrics & Gynecology and Reproductive Biology, 152, 96-102. https://doi.org/10.1016/j.ejogrb.2010.05.012
[16]
Kaushal, D.A., Gupta, D.D.P.D. and Kumar, D.A. (2020) Clinicopathological Profile of Uterine Fibroid at a Medical College Hospital. Tropical Journal of Pathology and Microbiology, 6, 155-160. https://doi.org/10.17511/jopm.2020.i02.07
[17]
Ghant, M.S., Sengoba, K.S., Recht, H., Cameron, K.A., Lawson, A.K. and Marsh, E.E. (2015) Beyond the Physical: A Qualitative Assessment of the Burden of Symptomatic Uterine Fibroids on Women’s Emotional and Psychosocial Health. Journal of Psychosomatic Research, 78, 499-503. https://doi.org/10.1016/j.jpsychores.2014.12.016
[18]
Pavone, D., Clemenza, S., Sorbi, F., Fambrini, M. and Petraglia, F. (2018) Epidemiology and Risk Factors of Uterine Fibroids. Best Practice & Research Clinical Obstetrics & Gynaecology, 46, 3-11. https://doi.org/10.1016/j.bpobgyn.2017.09.004
[19]
Borah, B.J., Nicholson, W.K., Bradley, L. and Stewart, E.A. (2013) The Impact of Uterine Leiomyomas: A National Survey of Affected Women. American Journal of Obstetrics and Gynecology, 209, 319.e1-319.e20. https://doi.org/10.1016/j.ajog.2013.07.017
[20]
Laberge, P.Y., Vilos, G.A., Vilos, A.G. and Janiszewski, P.M. (2015) Burden of Symptomatic Uterine Fibroids in Canadian Women: A Cohort Study. Current Medical Research and Opinion, 32, 165-175. https://doi.org/10.1185/03007995.2015.1107534
[21]
Hemmings, R., Rivard, M., Olive, D.L., Poliquin-Fleury, J., Gagné, D., Hugo, P., et al. (2004) Evaluation of Risk Factors Associated with Endometriosis. Fertility and Sterility, 81, 1513-1521. https://doi.org/10.1016/j.fertnstert.2003.10.038
[22]
de Oliveira, R., Adami, F., Mafra, F.A., Bianco, B., Vilarino, F.L. and Barbosa, C.P. (2016) Causes of Endometriosis and Prevalent Infertility in Patients Undergoing Laparoscopy without Achieving Pregnancy. Minerva Ginecologica, 68, 250-258.
[23]
R Core Team (2021) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/
[24]
Hartmann, K.E., Fonnesbeck, C., Surawicz, T., et al. (2023) Management of Uterine Fibroids. https://www.ncbi.nlm.nih.gov/books/NBK537747/
[25]
Katon, J.G., Plowden, T.C. and Marsh, E.E. (2023) Racial Disparities in Uterine Fibroids and Endometriosis: A Systematic Review and Application of Social, Structural, and Political Context. Fertility and Sterility, 119, 355-363. https://doi.org/10.1016/j.fertnstert.2023.01.022
[26]
Hemmert, R., Schliep, K.C., Willis, S., Peterson, C.M., Louis, G.B., Allen-Brady, K., et al. (2018) Modifiable Life Style Factors and Risk for Incident Endometriosis. Paediatric and Perinatal Epidemiology, 33, 19-25. https://doi.org/10.1111/ppe.12516
[27]
Marino, J.L., Eskenazi, B., Warner, M., Samuels, S., Vercellini, P., Gavoni, N., et al. (2004) Uterine Leiomyoma and Menstrual Cycle Characteristics in a Population-Based Cohort Study. Human Reproduction, 19, 2350-2355. https://doi.org/10.1093/humrep/deh407
[28]
Wise, L.A. (2004) Reproductive Factors, Hormonal Contraception, and Risk of Uterine Leiomyomata in African-American Women: A Prospective Study. American Journal of Epidemiology, 159, 113-123. https://doi.org/10.1093/aje/kwh016
[29]
Freytag, D., Günther, V., Maass, N. and Alkatout, I. (2021) Uterine Fibroids and Infertility. Diagnostics, 11, Article No. 1455. https://doi.org/10.3390/diagnostics11081455
[30]
Wong, J.Y.Y., Gold, E.B., Johnson, W.O. and Lee, J.S. (2016) Circulating Sex Hormones and Risk of Uterine Fibroids: Study of Women’s Health across the Nation (SWAN). The Journal of Clinical Endocrinology & Metabolism, 101, 123-130. https://doi.org/10.1210/jc.2015-2935
[31]
Pritts, E.A., Parker, W.H. and Olive, D.L. (2009) Fibroids and Infertility: An Updated Systematic Review of the Evidence. Fertility and Sterility, 91, 1215-1223. https://doi.org/10.1016/j.fertnstert.2008.01.051
[32]
Moore, K.R., Cole, S.R., Dittmer, D.P., Schoenbach, V.J., Smith, J.S. and Baird, D.D. (2015) Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women. Journal of Women’s Health, 24, 489-495. https://doi.org/10.1089/jwh.2014.5051
[33]
Moore, K.R., Harmon, Q.E., Zhao, S., Taylor, B.D. and Baird, D.D. (2022) Bacterial Vaginosis and Prospective Ultrasound Measures of Uterine Fibroid Incidence and Growth. Epidemiology, 33, 415-421. https://doi.org/10.1097/ede.0000000000001463
[34]
Moore, K.R., Smith, J.S., Laughlin-Tommaso, S.K. and Baird, D.D. (2014) Cervical Neoplasia–Related Factors and Decreased Prevalence of Uterine Fibroids among a Cohort of African American Women. Fertility and Sterility, 101, 208-214. https://doi.org/10.1016/j.fertnstert.2013.09.021
[35]
Neufingerl, N., Cobain, M.R. and Newson, R.S. (2014) Web-Based Self-Assessment Health Tools: Who Are the Users and What Is the Impact of Missing Input Information? Journal of Medical Internet Research, 16, e215. https://doi.org/10.2196/jmir.3146
[36]
Strömgren, A.S., Goldschmidt, D., Groenvold, M., Petersen, M.A., Jensen, P.T., Pedersen, L., et al. (2002) Self-Assessment in Cancer Patients Referred to Palliative Care. Cancer, 94, 512-520. https://doi.org/10.1002/cncr.10222
[37]
Zimmermann, A., Bernuit, D., Gerlinger, C., Schaefers, M. and Geppert, K. (2012) Prevalence, Symptoms and Management of Uterine Fibroids: An International Internet-Based Survey of 21,746 Women. BMC Women’s Health, 12, Article No. 6. https://doi.org/10.1186/1472-6874-12-6
[38]
Myers, S.L., Baird, D.D., Olshan, A.F., Herring, A.H., Schroeder, J.C., Nylander-French, L.A., et al. (2012) Self-Report versus Ultrasound Measurement of Uterine Fibroid Status. Journal of Women’s Health, 21, 285-293. https://doi.org/10.1089/jwh.2011.3008
[39]
Day Baird, D. and Dunson, D.B. (2003) Why Is Parity Protective for Uterine Fibroids? Epidemiology, 14, 247-250. https://doi.org/10.1097/01.ede.0000054360.61254.27
Borahay, M.A., Asoglu, M.R., Mas, A., Adam, S., Kilic, G.S. and Al-Hendy, A. (2017) Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications. Reproductive Sciences, 24, 1235-1244. https://doi.org/10.1177/1933719116678686
[42]
Asada, H., Yamagata, Y., Taketani, T., Matsuoka, A., Tamura, H., Hattori, N., et al. (2008) Potential Link between Estrogen Receptor-Gene Hypomethylation and Uterine Fibroid Formation. Molecular Human Reproduction, 14, 539-545. https://doi.org/10.1093/molehr/gan045
[43]
Kwas, K., Nowakowska, A., Fornalczyk, A., Krzycka, M., Nowak, A., Wilczyński, J., et al. (2021) Impact of Contraception on Uterine Fibroids. Medicina, 57, Article No. 717. https://doi.org/10.3390/medicina57070717
[44]
Wang, Y., Nisenblat, V., Tao, L., Zhang, X., Li, H. and Ma, C. (2019) Combined Estrogen-Progestin Pill Is a Safe and Effective Option for Endometrial Hyperplasia without Atypia: A Three-Year Single Center Experience. Journal of Gynecologic Oncology, 30, e49. https://doi.org/10.3802/jgo.2019.30.e49
[45]
Hartmann, K.E., Velez Edwards, D.R., Savitz, D.A., Jonsson-Funk, M.L., Wu, P., Sundermann, A.C., et al. (2017) Prospective Cohort Study of Uterine Fibroids and Miscarriage Risk. American Journal of Epidemiology, 186, 1140-1148. https://doi.org/10.1093/aje/kwx062
[46]
Choudhary, A., Inamdar, S.A. and Sharma, U. (2023) Pregnancy with Uterine Fibroids: Obstetric Outcome at a Tertiary Care Hospital of Central India. Cureus, 15, e35513. https://doi.org/10.7759/cureus.35513
[47]
Zhao, R., Wang, X., Zou, L., Li, G., Chen, Y., Li, C., et al. (2017) Adverse Obstetric Outcomes in Pregnant Women with Uterine Fibroids in China: A Multicenter Survey Involving 112,403 Deliveries. PLOS ONE, 12, e0187821. https://doi.org/10.1371/journal.pone.0187821
[48]
Navarro, A., Bariani, M.V., Yang, Q. and Al-Hendy, A. (2021) Understanding the Impact of Uterine Fibroids on Human Endometrium Function. Frontiers in Cell and Developmental Biology, 9, Article 633180. https://doi.org/10.3389/fcell.2021.633180
[49]
Uimari, O., Subramaniam, K.S., Vollenhoven, B. and Tapmeier, T.T. (2022) Uterine Fibroids (Leiomyomata) and Heavy Menstrual Bleeding. Frontiers in Reproductive Health, 4, Article 818243. https://doi.org/10.3389/frph.2022.818243
[50]
American College of Obstetricians and Gynecologists (2008) ACOG Practice Bulletin. Alternatives to Hysterectomy in the Management of Leiomyomas. Obstetrics & Gynecology, 112, 387-400.
[51]
Tak, Y.J., Lee, S.Y., et al. (2016) Association between Uterine Leiomyoma and Metabolic Syndrome in Parous Premenopausal Women: A Case-Control Study. Medicine, 95, e5325.
[52]
Eckel, R.H., Grundy, S.M. and Zimmet, P.Z. (2005) The Metabolic Syndrome. The Lancet, 365, 1415-1428. https://doi.org/10.1016/s0140-6736(05)66378-7
[53]
Hebbar, S., Chaya, V., Rai, L. and Ramachandran, A. (2014) Factors Influencing Endometrial Thickness in Postmenopausal Women. Annals of Medical and Health Sciences Research, 4, 608-614. https://doi.org/10.4103/2141-9248.139340
[54]
Tseng, C. (2019) Metformin Use Is Associated with a Lower Risk of Uterine Leiomyoma in Female Type 2 Diabetes Patients. Therapeutic Advances in Endocrinology and Metabolism, 10, Article 204201881989515. https://doi.org/10.1177/2042018819895159
[55]
Mitro, S.D., Wise, L.A., Waetjen, L.E., Lee, C., Zaritsky, E., Harlow, S.D., et al. (2024) Hypertension, Cardiovascular Risk Factors, and Uterine Fibroid Diagnosis in Midlife. JAMA Network Open, 7, e246832. https://doi.org/10.1001/jamanetworkopen.2024.6832
[56]
Stewart, E.A. and Borah, B.J. (2020) Uterine Fibroids and Hypertension: Steps toward Understanding the Link. The Journal of Clinical Endocrinology & Metabolism, 106, e1039-e1041. https://doi.org/10.1210/clinem/dgaa829
[57]
Kirschen, G.W., AlAshqar, A., Miyashita-Ishiwata, M., Reschke, L., El Sabeh, M. and Borahay, M.A. (2021) Vascular Biology of Uterine Fibroids: Connecting Fibroids and Vascular Disorders. Reproduction, 162, R1-R18. https://doi.org/10.1530/rep-21-0087
[58]
Flores-Caldera, I., Ramos-Echevarría, P.M., Oliveras-Torres, J.A., Santos-Piñero, N., Rivera-Mudafort, E.D., Soto-Soto, D.M., et al. (2021) Ibero-American Endometriosis Patient Phenome: Demographics, Obstetric-Gynecologic Traits, and Symptomatology. Frontiers in Reproductive Health, 3, Article 667345. https://doi.org/10.3389/frph.2021.667345
